Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,918 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Umino K, Nakano H, Morita K, Yamasaki R, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y. Yamamoto C, et al. Among authors: nakashima h. Blood. 2022 Aug 11;140(6):594-607. doi: 10.1182/blood.2021015220. Blood. 2022. PMID: 35580269 Free PMC article.
Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation.
Yamamoto C, Nakashima H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Mashima K, Nagayama T, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Sugimoto M, Ishihara Y, Ashizawa M, Hatano K, Sato K, Oh I, Fujiwara SI, Ueda M, Ohmine K, Muroi K, Kanda Y. Yamamoto C, et al. Among authors: nakashima h. Blood Adv. 2019 Nov 12;3(21):3266-3277. doi: 10.1182/bloodadvances.2019000745. Blood Adv. 2019. PMID: 31698458 Free PMC article.
Clinical association between thyroid disease and immune thrombocytopenia.
Ito S, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ban T, Nagayama T, Umino K, Minakata D, Morita K, Nakano H, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Kanda Y. Ito S, et al. Among authors: nakashima h. Ann Hematol. 2021 Feb;100(2):345-352. doi: 10.1007/s00277-020-04343-5. Epub 2020 Nov 9. Ann Hematol. 2021. PMID: 33165625 Clinical Trial.
Risk factors for high-dose methotrexate-induced nephrotoxicity.
Kawaguchi S, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, Ito S, Ban T, Nagayama T, Umino K, Minakata D, Nakano H, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Kanda Y. Kawaguchi S, et al. Among authors: nakashima h. Int J Hematol. 2021 Jul;114(1):79-84. doi: 10.1007/s12185-021-03132-8. Epub 2021 Mar 20. Int J Hematol. 2021. PMID: 33743109
Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis.
Minakata D, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Minakata D, et al. Among authors: nakashima h. Leuk Res. 2022 Jan;112:106750. doi: 10.1016/j.leukres.2021.106750. Epub 2021 Nov 11. Leuk Res. 2022. PMID: 34798568
Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation.
Nagayama T, Fujiwara SI, Kikuchi T, Onda K, Murahashi R, Nakashima H, Ikeda T, Matsuoka S, Kawaguchi SI, Toda Y, Ito S, Ban T, Umino K, Minakata D, Nakano H, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Kanda Y. Nagayama T, et al. Among authors: nakashima h. Leuk Lymphoma. 2022 Jul;63(7):1694-1700. doi: 10.1080/10428194.2022.2034159. Epub 2022 Feb 14. Leuk Lymphoma. 2022. PMID: 35156892
Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome.
Ito S, Fujiwara SI, Yoshizawa T, Hayatsu K, Sekiguchi K, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, Kawaguchi S, Nagayama T, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Ito S, et al. Among authors: nakashima h. Intern Med. 2022 Nov 1;61(21):3271-3275. doi: 10.2169/internalmedicine.9332-22. Epub 2022 Apr 2. Intern Med. 2022. PMID: 35370238 Free PMC article.
Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation.
Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, Ito S, Kawaguchi SI, Nagayama T, Umino K, Minakata D, Morita K, Nakano H, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Fujiwara SI, et al. Among authors: nakashima h. Leuk Res. 2022 Oct;121:106951. doi: 10.1016/j.leukres.2022.106951. Epub 2022 Sep 12. Leuk Res. 2022. PMID: 36115066
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies.
Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Minakata D, et al. Among authors: nakashima h. Br J Haematol. 2023 Mar;200(6):694-703. doi: 10.1111/bjh.18654. Epub 2023 Jan 20. Br J Haematol. 2023. PMID: 36661264 Review.
Early reversal of the lymphocyte-to-monocyte ratio after allogeneic-hematopoietic stem cell transplantation is associated with reduced relapse and improved prognosis.
Nagayama T, Fujiwara SI, Tominaga R, Yokoyama D, Noguchi A, Furuki S, Oyama T, Koyama S, Murahashi R, Nakashima H, Ikeda T, Hyodo K, Kawaguchi SI, Toda Y, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Nagayama T, et al. Among authors: nakashima h. Clin Transplant. 2023 Dec;37(12):e15116. doi: 10.1111/ctr.15116. Epub 2023 Aug 29. Clin Transplant. 2023. PMID: 37641561
1,918 results